Skip to main content
SpringerLink
Log in
Book cover

Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik pp 221–239Cite as

Behandlungsergebnisse mit präsynaptischen und postsynaptischen Dopamin-Agonisten bei Minussymptomatik

  • Chapter

Zusammenfassung

Ähnlich wie für Antidepressiva wird auch bei der Entwicklung von neuen Neuroleptika (Übersicht siehe Tabelle 1) u. a. das Ziel verfolgt, bei gleicher bzw. besserer therapeutischer Wirkung ein günstigeres Nebenwirkungsprofil zu erreichen. Die zur Zeit im Handel befindlichen Neuroleptika unterscheiden sich einerseits hinsichtlich der Stärke und Spezifität der Dopamin-Rezeptorblockade und andererseits hinsichtlich der Wirkung auf weitere Rezeptoren (z. B.: histaminerg, muskarinisch, serotonerg, alpha-adrenerg). Die unterschiedliche Wirkung auf diese Rezeptoren, aber auch auf Dopamin-Subtypen (D1, D2) und dabei deren toposelektive Präferenz bestimmen sowohl die Wirkung als auch das Nebenwirkungsprofil.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anden NE, Golembiowska-Nikitin K, Thornstrom U (1982) Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively. Naunyn Schmiedebergs Arch Pharmacol 321: 100–104

    Article  PubMed  CAS  Google Scholar 

  • Andreasen NC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39: 784–794

    Article  PubMed  CAS  Google Scholar 

  • Amt J, Hyttel J (1984) Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxydopamine lesions and by chronic reserpine treatment in rats. J Neural Transm 60: 205–223

    Article  Google Scholar 

  • Benkert O, Holsboer F (1984) Effect of sulpiride in endogenous depression. Acta Psychiatr Scand [Suppl] 311: 43–48

    Article  CAS  Google Scholar 

  • Benkert O, Gründer G, Wetzel H (1992) Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 25: 254–260

    Article  PubMed  CAS  Google Scholar 

  • Brambilla F, Scarone S, Pugnetti L, Massironi R, Penati G, Nobile P (1983) Bromocriptine therapy in chronic schizophrenia. Effects on symptomatology, sleep patterns and prolactin response to stimulation. Psychiatry Res 8: 159–169

    Google Scholar 

  • Brücke T, Danielczky W, Simanyi M, Sofic E, Riederer P (1986) Terguride: partial dopamine agonist in the treatment of Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 573–576

    Google Scholar 

  • Bunzow JR, van Tol HHM, Grandy DK, Alter P, Salon J, Christie M, Machida CA, Neve KA, 238 S. Kasper et al.

    Google Scholar 

  • Civelli O (1988) Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336: 783–787

    Article  PubMed  Google Scholar 

  • Carlsson A (1975) Receptor-mediated control of dopamine metabolism. In: Usdin E, Bunney WE Jr (eds) Pre-and postsynaptic receptors. Marcel Dekker, New York, pp 49–65

    Google Scholar 

  • Carlsson A (1988) The dopamine hypothesis of schizophrenia 20 years later. In: Häfner H, Gattaz WF, Janzarik W (eds) Search for the causes of schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 223–235

    Google Scholar 

  • Carlsson A (1991) Das antipsychotische Potential von dopaminergen Liganden. In: Beckmann H, Osterheider M (Hrsg) Tropon-Symposium, Bd Vl. Springer, Berlin Heidelberg New York Tokyo, S 135–144

    Google Scholar 

  • Coward D, Dixon K, Enz A, Sherman G, Urwyler S, White T, Karobath M (1989) Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia. Psychopharmacol Bull 25: 393–397

    PubMed  CAS  Google Scholar 

  • Coward D, Dixon K, Urwyler S (1990) Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208–911 and SDZ 208–912. J Pharmacol Exp Ther 252: 279–285

    PubMed  CAS  Google Scholar 

  • Davidson M, Kendler KS, Davis BM, Horvath TB, Mohs RC, Davis KL (1985) Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients. Psychiatry Res 16: 95–99

    Article  PubMed  CAS  Google Scholar 

  • Fritze J (1992) Neurobiochemie, Wirkungsmechanismen. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuropsychopharmaka, Bd 4. Neuroleptika. Springer, Wien New York, S 59–80

    Google Scholar 

  • Gerbaldo H, Demisch I, Lehmann CO, Bochnik J (1988) The effect of OPC-4392, a partial dopamine receptor agonist, on negative symptoms. Results of an open study. Pharmacopsychiatry 21: 387–388

    Google Scholar 

  • Gründer G, Wetzel H, Hammes E, Benkert O (1992) Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psy Clin Neuropharm 15 [Suppl 1, Pt B]: 175B

    Google Scholar 

  • Hinzen D, Hornykiewicz O, Kobinger W, Pichler L, Pifl C, Schingnitz G (1986) The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of parkinson’s disease a novel approach to treatment. Eur J Pharmacol 131: 75–86

    Article  PubMed  CAS  Google Scholar 

  • Jimerson DC (1987) Role of dopamine mechanisms in the affective disorders. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 505–512

    Google Scholar 

  • Kasper S, Fuger J, Zimmer HJ, Bäuml J, Möller HJ (1992) Early clinical results with the neuroleptic roxindole (EMD 49980) in the treatment of schizophrenia — an open study. Eur Neuropsychopharmacol 2: 91–95

    Article  PubMed  CAS  Google Scholar 

  • Kasper S, Fuger J, Möller HJ (1992) Comparative efficacy of antidepressants. Drugs [Suppl] 43: 11–23

    Google Scholar 

  • Kissling W, Mackert A, Bäuml J, Lauter H (1992) Erste klinische Erfahrungen mit dem neuen Dopamin-Autorezeptoragonisten SND 919. In: Gaebel W, Laux G (Hrsg) Biologische Psychiatrie. Synopsis 90/91. Springer, Berlin Heidelberg New York Tokyo, S 256–249

    Chapter  Google Scholar 

  • Klimke A, Klieser E (1991) Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (roxindole). Pharmacopsychiatry 24: 107–112

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY (1980) Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies. Schizophr Bull 6: 456–475

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Kolakowska T, Robertson A, Tricon BJ (1983) Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy. Psychopharmacology 81: 37–41

    Article  PubMed  CAS  Google Scholar 

  • Mireau J, Schingnitz G (1991) Biochemical and pharmacological studies on pramipexol, a potent and selective D-2 dopamine receptor agonist. Eur J Pharmacol 136: 12–19

    Google Scholar 

  • Möller HJ (1992) Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 3: 1–11

    Article  Google Scholar 

  • Naher D, Gaussares C, „SDZ HDC 912 Collaborative Study Group“. In: Moegelen JM, Tremmel L, Bailey PE (1992) Wirksamkeit und Verträglichkeit des Dopamin-Agonisten/Antagonisten SDZ HDC 912 in der Therapie schizophrener Patienten. In: Gaebel W, Laux G (Hrsg) Biologische Psychiatrie. Synopsis 90/91. Springer, Berlin Heidelberg New York Tokyo, S 245–249

    Google Scholar 

  • Olbrich R, Schanz H (1988) The effect of the partial dopamin agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21: 389–390

    Article  PubMed  CAS  Google Scholar 

  • Olbrich R, Schanz H (1991) An evaluation of the partial dopamine agonist terguride on negative symptoms in schizophrenia. J Neural Transm [Gen Sect] 84: 233–236

    Article  CAS  Google Scholar 

  • Pichler L, Kobinger W (1981) Centrally mediated cardiovascular effects of B-HT 920 (6-allyl2-amino-5,6 7,8-tetrahydro-4H-thiazolo (4,5-djazepine dihydrochloride), a hypotensive agent of the clonidine type. J Cardiovasc Pharmacol 3: 269–277

    Article  PubMed  CAS  Google Scholar 

  • Roth RH, Wolf ME, Deutsch AY (1987) Neurochemistry of midbrain dopamine systems. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 81–94

    Google Scholar 

  • Serra G, Forgione A, d’Aquila PS, Colin M, Fratta W, Gessa GL (1990) Blockade of DA autoreceptors: possible mechanism of antidepressant action of L-sulpiride. Adv Biosci 77: 185–191

    CAS  Google Scholar 

  • Seyfried CA, Greiner HE, Haase AF (1989) Biochemical and functional studies on EMD 49980: a potent, selectively presynaptic D2 dopamine agonist with actions on serotonin systems. Eur J Pharmacol 160: 31–41

    Article  PubMed  CAS  Google Scholar 

  • Seyfried CA, Boettcher H (1990) Central D2-autoreceptor agonists, with special reference to indolylbutylamines. Drugs of the Future 8: 819–832

    Google Scholar 

  • Sokoloff P, Giros B, Martres MP, Boutenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor ( D3) as a target for neuroleptics. Nature 347: 146–151

    Google Scholar 

  • Tamminga CA, Schaffer MH, Smith RC (1978) Schizophrenic symptoms improve with apomorphine. Science 200: 567–568

    Article  PubMed  CAS  Google Scholar 

  • Tamminga CA, Gotts MD, Miller MR (1983) N-propyl-norapomorphine in the treatment of schizophrenia. Acta Pharm Sued [Suppl] 2: 153–158

    Google Scholar 

  • van Kammen DP, van Kammen WB, Mann LS, Seppala T, Linnoila M (1986) Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 43: 978–983

    Article  PubMed  Google Scholar 

  • Wachtel H, Dorow R (1983) Dual action on central dopamine function of trans-dihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuricle. Life Sci 32: 421–432

    Article  PubMed  CAS  Google Scholar 

  • Wetzel H, Benkert O (1990) Neuroleptika: Neue Substanzen–Neue Indikation. In: Herz VA, Hippius A, Spann W (Hrsg) Psychopharmaka heute. Springer, Berlin Heidelberg New York Tokyo, S 108–128

    Chapter  Google Scholar 

  • Wetzel H, Gründer G, Hillert A, Hiemke C, Benkert O (1993) Neuroendocrinological and EEG sleep effects of Roxindole, a dopamine autoreceptor agonist in schizophrenic and depressed patients. Clin Neuropharm 15 [Suppl 1B]: 602 B

    Google Scholar 

  • Wetzel H, Hillert A, Gründer G, Benkert 0 (1994) Roxindole a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenia. Am J Psychiatry (im Druck )

    Google Scholar 

  • Wetzel H, Benkert 0 (1994) Dopamin autoreceptor agonists in the treatment of schizophrenic disorders. Prog Neuropsychopharmacol Biol Psychiatry 17: 525–540

    Google Scholar 

  • Wiedemann K, Benkert O, Holsboer F (1990) B-HT 920–a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry 23: 50–55

    Article  PubMed  CAS  Google Scholar 

  • Wiedemann K, Loycke A, Krieg JC, Holsboer F (1991) EMD 49980 - a novel dopamine auto-receptor agonist in the treatment of schizophrenic patients with negative symptoms. Biol Psychiatry [Suppl] 29: 422 S

    Google Scholar 

  • Willner P (1983) Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res Rev 6: 211–224

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatrische Universitätsklinik, Bonn, Bundesrepublik Deutschland

    o.Univ.Prof. Dr. S. Kasper, P. Danos, G. Höflich & H.-J. Möller

Authors
  1. o.Univ.Prof. Dr. S. Kasper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Danos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Höflich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.-J. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik und Poliklinik, Sigmund-Freud-Straße 25, D-53105, Bonn, Deutschland

    Hans-Jürgen Möller  & Gerd Laux  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag/Wien

About this chapter

Cite this chapter

Kasper, S., Danos, P., Höflich, G., Möller, HJ. (1994). Behandlungsergebnisse mit präsynaptischen und postsynaptischen Dopamin-Agonisten bei Minussymptomatik. In: Möller, HJ., Laux, G. (eds) Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9349-5_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9349-5_19

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82547-1

  • Online ISBN: 978-3-7091-9349-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation